Inhibitor Therapeutics, Inc. (INTI) — SEC Filings
Inhibitor Therapeutics, Inc. (INTI) — 10 SEC filings. Latest: 8-K (Apr 1, 2026). Includes 6 10-Q, 2 8-K, 2 10-K.
View Inhibitor Therapeutics, Inc. on SEC EDGAR
Overview
Inhibitor Therapeutics, Inc. (INTI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Inhibitor Therapeutics, Inc. (INTI) reported a net loss of $2,004,972 for the nine months ended September 30, 2025, an increase from the $1,917,358 net loss in the same period of 2024. The company generated no revenue in either period. Cash and cash equivalents significantly decreased to $2,976,658
Sentiment Summary
Across 10 filings, the sentiment breakdown is: 2 bearish, 8 neutral. The dominant filing sentiment for Inhibitor Therapeutics, Inc. is neutral.
Filing Type Overview
Inhibitor Therapeutics, Inc. (INTI) has filed 2 8-K, 6 10-Q, 2 10-K with the SEC between Mar 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (10)
| Date | Form | Description | Risk |
|---|---|---|---|
| Apr 1, 2026 | 8-K | 8-K Filing | |
| Nov 13, 2025 | 10-Q | Inhibitor Therapeutics' Cash Dwindles Amid Rising R&D Costs | high |
| Oct 27, 2025 | 8-K | Inhibitor Therapeutics: Director Departs, New Director Appointed | medium |
| Aug 13, 2025 | 10-Q | Inhibitor Therapeutics' Losses Widen Amid R&D Spend, Cash Dwindles | high |
| May 14, 2025 | 10-Q | Inhibitor Therapeutics Files Q1 2025 10-Q | low |
| Mar 28, 2025 | 10-K | Inhibitor Therapeutics Files 2024 Annual Report | medium |
| Nov 12, 2024 | 10-Q | Inhibitor Therapeutics Files Q3 2024 10-Q | low |
| Aug 6, 2024 | 10-Q | Inhibitor Therapeutics Files Q2 2024 10-Q | medium |
| May 13, 2024 | 10-Q | Inhibitor Therapeutics, Inc. Files 10-Q for Q1 2024 | low |
| Mar 29, 2024 | 10-K | Inhibitor Therapeutics, Inc. Files 2023 Annual Report on Form 10-K | medium |
Risk Profile
Risk Assessment: Of INTI's 9 recent filings, 2 were flagged as high-risk, 4 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$2,004,972 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $2,976,658 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Niraj Vasisht
- Dr. David M. Lerner
- Dr. Robert L. Johnson
Industry Context
The oncology drug development landscape is highly competitive and capital-intensive, with significant R&D investment required for clinical trials and regulatory approvals. Companies like INTI are often focused on niche indications or novel formulations of existing compounds to carve out market share. The success of such ventures is heavily dependent on demonstrating clear clinical benefit and navigating complex regulatory pathways.
Top Tags
10-Q (4) · financials (3) · Biotechnology (2) · Cash Burn (2) · FDA Approval (2) · Oncology (2) · pharmaceuticals (2) · 10-K (2) · Inhibitor Therapeutics (2) · Pharmaceuticals (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $2,004,972 | for the nine months ended September 30, 2025, an increase from $1,917,358 in 2024 |
| Cash and Cash Equivalents | $2,976,658 | as of September 30, 2025, down from $5,606,863 at December 31, 2024 |
| Net Cash Used in Operating Activities | $2,630,205 | for the nine months ended September 30, 2025 |
| Research and Development Expenses | $939,470 | for the nine months ended September 30, 2025, up from $869,756 in 2024 |
| General and Administrative Expenses | $1,172,069 | for the nine months ended September 30, 2025, down from $1,303,404 in 2024 |
| Deferred Revenue | $3,000,000 | from royalties advanced by Mayne Pharma, classified as non-current |
| Common Stock Shares Outstanding | 172,573,545 | as of September 30, 2025 |
| Total Stockholders' Equity | $3,453 | as of September 30, 2025, a significant decrease from $1,985,040 at December 31, 2024 |
| Upfront License Fee | $40,000 | paid to Johns Hopkins University on December 12, 2023 |
| Aggregate Development-Related Milestone Payments | $3.0 million | owed to Johns Hopkins University upon achieving milestones |
| SEC File Number | 001-13467 | Identifies the company's registration with the SEC. |
| SIC Code | 2834 | Indicates the company operates in the Pharmaceutical Preparations industry. |
| Fiscal Year End | 2024-12-31 | Reporting period for the 10-K |
| Filing Date | 2025-03-28 | Date the 10-K was submitted to the SEC |
| Reporting Period End Date | 20240930 | Indicates the end of the fiscal quarter being reported. |
Frequently Asked Questions
What are the latest SEC filings for Inhibitor Therapeutics, Inc. (INTI)?
Inhibitor Therapeutics, Inc. has 10 recent SEC filings from Mar 2024 to Apr 2026, including 6 10-Q, 2 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of INTI filings?
Across 10 filings, the sentiment breakdown is: 2 bearish, 8 neutral. The dominant sentiment is neutral.
Where can I find Inhibitor Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Inhibitor Therapeutics, Inc. (INTI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Inhibitor Therapeutics, Inc.?
Key financial highlights from Inhibitor Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for INTI?
The investment thesis for INTI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Inhibitor Therapeutics, Inc.?
Key executives identified across Inhibitor Therapeutics, Inc.'s filings include Niraj Vasisht, Dr. David M. Lerner, Dr. Robert L. Johnson.
What are the main risk factors for Inhibitor Therapeutics, Inc. stock?
Of INTI's 9 assessed filings, 2 were flagged high-risk, 4 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Inhibitor Therapeutics, Inc.?
Forward guidance and predictions for Inhibitor Therapeutics, Inc. are extracted from SEC filings as they are enriched.